Table 2.

Retrospective SPC results (Good control level) at week 12

Study	Treatment Group	Safe Psoriasis Control (SPC)*
ACD2058[14]	Placebo (n = 170)	18 (10.6 %)
	Efalizumab 1.0 mg/kg/wk (n = 162)	75 (46.3 %)
ACD2059[13]	Placebo (n = 122)	12 (9.8 %)
	Efalizumab 1.0 mg/kg/wk (n = 232)	86 (37.1 %)
ACD2390[12]	Placebo (n = 187)	20 (10.7 %)
	Efalizumab 1.0 mg/kg/wk (n = 369)	140 (37.9 %)
Pooled studies	Placebo (n = 479)	50 (10.4%)
	Efalizumab 1.0 mg/kg/wk (n = 763)	301 (39.4%)

* SPC is defined by PASI <= 8 and DLQI <= 6 and No SAEs and No Severe AEs related to Study Drug and not withdrawn